Tafetinib
Code | Size | Price |
---|
TAR-T28911-1mg | 1mg | £271.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28911-5mg | 5mg | £571.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28911-10mg | 10mg | £783.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28911-25mg | 25mg | £1,139.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28911-50mg | 50mg | £1,500.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28911-100mg | 100mg | £2,022.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28911-500mg | 500mg | £3,990.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Tafetinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor used for the treatment of solid tumors.
CAS:
1032265-57-8
Formula:
C24H29FN4O2
Molecular Weight:
424.52
Pathway:
Tyrosine Kinase/Adaptors
Purity:
0.98
SMILES:
CCN(CC)CCNC(=O)c1c(C)[nH]c2c1CCCC2=C1C(=O)Nc2ccc(F)cc12
Target:
Tyrosine Kinases
References
1. Shao F, Zhu T, Tang F, Liu X. Simultaneous quantification of tafetinib (SIM010603), a novel potent inhibitor of receptor tyrosine kinase, and its major metabolite in dog plasma by HPLC-ESI/MS/MS and its application to a pharmacokinetic study. J Pharm Biomed Anal. 2013 Jul-Aug;81-82:50-5. doi: 10.1016/j.jpba.2013.02.041. PubMed PMID: 23624508.
2. Mao Y, Xia Z, Zhang X, Zong Y, Zhu L, Yuan B, Lu G. Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs. Food Chem Toxicol. 2012 May;50(5):1256-70. doi: 10.1016/j.fct.2012.02.007. PubMed PMID: 22343322.
3. Wang D, Tang F, Wang S, Jiang Z, Zhang L. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor. Cancer Chemother Pharmacol. 2012 Jan;69(1):173-83. doi: 10.1007/s00280-011-1681-1. PubMed PMID: 21638122.